HISOAR(SZ:002099) Zheng Quan Ri Bao·2025-04-29 00:09Group 1 - The company raised a total of RMB 1,026.87 million through a non-public offering of 99.89 million shares at a price of RMB 10.28 per share, with net proceeds amounting to RMB 1,014.40 million after deducting fees [2][3] - The company has established a dedicated account for the management of raised funds, signing tripartite and quadripartite supervision agreements with relevant banks and sponsors to ensure proper fund usage [3][4] - As of December 31, 2024, the company maintained one dedicated account for the raised funds [4] Group 2 - The company reported that the actual use of raised funds has been delayed for several projects, including the "Pharmaceutical Comprehensive R&D Center" and "Environmental Facility Renovation Project," due to strategic adjustments and external factors [5][6] - The "Pharmaceutical Comprehensive R&D Center" project was transferred to a subsidiary, and the implementation location was changed, leading to delays in investment progress [5][6] - The company stated that the benefits of certain projects cannot be individually accounted for, as their effectiveness is reflected indirectly through product quality improvements [7][10] Group 3 - The company reported a net loss of RMB 330.27 million for the year 2024, with total revenue of RMB 1,938.47 million [24][28] - The company proposed not to distribute cash dividends for 2024 due to the reported losses, aligning with its dividend policy [28] - The company has established a robust internal control system, ensuring compliance with relevant laws and regulations [31]